The frequency of severe (≥Grade 3) diarrhea in Study 3004 was substantially higher in the neratinib arm (39.8%) compared to the placebo arm (1.6%). A summary of characteristics of treatment-emergent diarrhea in Study 3004 is shown in the Tables below.